• Blog
  • Human Growth Hormone Market Analysis | 2022-2028

    Human Growth Hormone Market Analysis | 2022-2028

    Human Growth Hormone Market Analysis | 2022-2028
    Report code - SR2543 Delivery - 2 Weeks
    Human Growth Hormone Market Size, Share, Trend, Forecast, Competitive Analysis & Growt See more...

    Market Insights

    The Human Growth Hormone Market was estimated at US$ 4.1 billion in 2021 and is expected to grow at a CAGR of 9.18% during 2022-2028 to reach US$ 8.9 billion by 2028.

    Wish to get a free sample? Register Here

    What is Human Growth Hormone?

    Human growth hormone (HGH), also referred to as somatotropin, is a peptide hormone that stimulates growth, cell reproduction, as well as cell regeneration in humans, making it essential for human development. In humans, growth hormone (GH) shortage occurs when the pituitary gland does not produce enough HGH. In humans, this deficit is addressed by subcutaneous injections of recombinant human growth hormone.

    Human growth hormone insufficiency can also be caused by genetic illnesses such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty with shorter-than-average height.

    Human Growth Hormone Market Report Overview

    Market Size in 2028

    US$ 8.9 billion

    Market Size in 2021

    US$ 4.1 billion

    Market Growth (2022-2028)

    9.18% CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Market Dynamics

    According to the American Academy of Pediatrics, growth hormone insufficiency in humans is a rare illness that affects less than one in 3,000 to one in 10,000 children in the United States.

    Currently, HGH is commonly abused as an anti-aging medication in older adults and by bodybuilders and sportsmen as a performance-enhancing anabolic substance. However, according to the USFDA, HGH is a restricted substance and has not been licensed for anti-aging or performance-enhancing purposes.

    Furthermore, many government and private organizations' activities to raise awareness about GH deficiency and human growth hormone treatment are projected to drive the market. Annually, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a nonprofit charitable organization based in the United States, commemorates International Children's Growth Awareness Day to raise awareness about the early detection and treatment of growth hormone disorders in humans, particularly children.

    Nevertheless, the high price of HGH therapies and severe HGH-related side effects may stymie market growth during the forecast period. For example, UPMC Children's Hospital of Pittsburgh reports that possible adverse effects of GH hormone therapy include knee, hip, or other joint discomfort; allergic reactions such as rash, swelling, or hives; and a spike in blood sugar levels.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

    • The human growth hormones market is likely to be driven by a robust product pipeline and extensive R&D initiatives for the development of innovative growth hormone therapies. In September 2018, Novo Nordisk presented Phase II clinical trial data for Somapacitan, an experimental GH medication recommended for treating pediatric growth hormone insufficiency.

    • Furthermore, Ascendis Pharma A/S announced Phase III clinical trial findings for their TransCon HGH, indicated for juvenile growth hormone insufficiency, in May 2019.

    Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences are also engaging in R&D initiatives to develop innovative human growth hormone therapy.

    Segment Analysis

    By Application Type

    The human growth hormone market is segmented into growth hormone deficiency, turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, and others. The GH deficiency category dominated the market and is projected to continue to do so throughout the forecast period. This is due to increased awareness regarding the early detection and treatment of GH insufficiency in people, as well as the entry of novel medications into the HGH market.

    For example, Ascendis Pharma A/S received an Orphan Designation from the European Commission (EC) in October 2018 for its investigational long-acting GH medication for humans, TransCon HGH, which is recommended for the treatment of pediatric GH deficiency.

    Similarly, Ferring Pharmaceuticals Inc. got USFDA approval in January 2018 for Zomacton (somatropin), a novel recombinant HGH intended for the treatment of adults with GH insufficiency. The GH deficiency category is further subdivided into adult and pediatric GH deficiency, with the latter expected to dominate the market over the projection period due to a rising number of pipeline medications.

    For example, Pfizer Inc. and its partner OPKO Health Inc. stated in October 2019 that their Phase III research of Somatrogon in pre-pubertal children with HGH fulfilled its primary endpoint of non-inferiority to daily somatropin. Turner's syndrome accounted for the second-largest market share in 2021 and is expected to emerge as a profitable category during the projected period. This can be explained by

    By Distribution Channel Type

    The market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacy segment held a sizable market share. This large percentage is ascribed to an increase in hospital visits due to increased human awareness of GH insufficiency and therapy. According to the Children's Hospital of Philadelphia (CHOP), growth hormone prescriptions have climbed from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 patients per 10,000 in 2016.

    Regional Analysis

    The human growth hormone market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Because of variables such as attractive reimbursement scenarios, established healthcare infrastructure, considerable government initiatives, and expanding healthcare awareness, North America is expected to account for the greatest share.

    Furthermore, the presence of significant firms in the region facilitates access to innovative pharmaceuticals, which benefits the North American market. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are three significant competitors based in the United States that provide a wide range of human GH medicines in the region. Over the forecast period, Asia Pacific is expected to grow at a rapid pace.

    Key competitors are focusing on attaining a significant market share in potential Asia Pacific nations such as Japan and China through product approval and launch. For example, in March 2017, Novo Nordisk A/S, a Danish pharmaceutical company, began a phase III clinical trial in Japan for their HGH somapacitan, which is designed for the treatment of adults with growth hormone insufficiency.

    Want to know which region offers the best growth opportunities? Register Here

    Key Players

    The following are the major players in the human growth hormone market:

    • Aeterna Zentaris
    • AnkeBio Co. Ltd
    • Eli Lilly and Company
    • EMD Serono Inc.
    • F. Hoffmann-La Roche Ltd
    • Ferring BV
    • GeneScience Pharmaceuticals Co. Ltd
    • Ipsen SA
    • LG Life Sciences
    • Novo Nordisk AS
    • Pfizer Inc.
    • Sandoz International GmbH (Novartis AG)
    • Sinobioway Hygiene Biomedicine Co. Ltd
    • Strongbridge Biopharma
    • Teva Pharmaceutical Industries Ltd

    Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc. (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, and Ipsen are some of the market's prominent participants. Several businesses are working on long-acting human growth hormones. Mergers, partnerships, as well as acquisitions are significant methods used by the market's leading players to extend their geographical scope and provide access to their products. For example,

    • In October 2018, Novo Nordisk and Strongbridge Biopharma agreed to buy the rights to MACRILEN in the United States and Canada. MACRILEN (macimorelin) is the first and only FDA-approved oral medication for the diagnosis of adult growth hormone insufficiency.

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Human Growth Hormone Market 

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market Segment Analysis and Forecast

    Who are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirements?

    10% free customization

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to 3 players).
    • SWOT analysis of key players (up to 3 players).

    Market Segmentation

    • Current market segmentation of any one of the product types by application type.  

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

     

    Frequently Asked Questions (FAQs)

    Human growth hormone (HGH), also referred to as somatotropin, is a peptide hormone that stimulates growth, cell reproduction, as well as cell regeneration in humans, making it essential for human development. In humans, growth hormone (GH) shortage occurs when the pituitary gland does not produce enough HGH. In humans, this deficit is addressed by subcutaneous injections of recombinant human growth hormone. Human growth hormone insufficiency can also be caused by genetic illnesses such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty with shorter-than-average height.

    The market is expected to grow at a CAGR of 9.18% during 2022-2028.

    The major players in the human growth hormone market are AnkeBio Co. Ltd, EMD Serono Inc., F. Hoffmann-La Roche Ltd, Ferring BV, Ipsen SA, Eli Lilly and Company, Novo Nordisk AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH (Novartis AG), Strongbridge Biopharma, GeneScience Pharmaceuticals Co. Ltd, Sinobioway Hygene Biomedicine Co. Ltd, Aeterna Zentaris, LG Life Sciences.

    The human growth hormone market size is projected to reach US$ 8.9 billion by 2028.

    North America is expected to be dominant in the market during the forecast period.

    The study period of the market is 2016-2028.